Breast Cancer NGS Panel

What is the SymGene Focus – Breast Cancer Panel?

The breast cancer panel is a validated genomic profile that includes 8 genes with compelling clinical and biological evidence as biomarkers to predict drug responses. The genes in our panel are connected with approved drugs in standard care or for off-label drugs in clinical trials.

Who Should Have this Test Run?

Genetic profiling of these genes is useful for assessing prognosis and guiding treatment of individuals with breast cancer. SymGene Breast can also be used to help determine clinical trial eligibility for patients with alterations in genes not amenable to current FDA-approved targeted therapies.

Test Details

• Designed for tumor profiling of primary or metastatic breast cancer.
• Assesses all coding exons of each gene for substitutions, insertions and deletions of less than 50 bp, and copy number variants (gene amplifications or homozygous loss).
• This test is performed to evaluate for somatic mutations within tumor samples; does not assess for germline alterations within the genes listed.

What Genes Are Included in the Breast Cancer Panel?

Healthcare providers with several options for ordering Sygmene for their patients including LabDOX, fax, and phone. Healthcare providers must first complete a test requisition form to start the process. Turn around times average 2 weeks from the time a specimen is received.